Study identifier:D0520C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open-label, single-centre, 3-way single dose crossover study to assess the relative bioavailability after oral administration of a tablet variant of AZD9668 compared to AZD9668 tablets and to further investigate the safety and tolerability of AZD9668 in healthy subjects
Chronic Obstructive Pulmonary Disease
Phase 1
Yes
AZD9668
All
15
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD9668 2X30mg tablet | Drug: AZD9668 2 x 30 mg batch DLE494 Drug: AZD9668 2 x 30 mg batch DLF497 Drug: AZD9668 2 x 30 mg tablet variant 1 |